XML 32 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Compensation and Employee Benefit Plans [Text Block]
12 Months Ended
Dec. 31, 2019
Notes  
Compensation and Employee Benefit Plans Note 14.Share-Based Compensation     In November 2016, the stockholders approved the Independence Holding Company 2016 Stock Incentive Plan (the “2016 Plan"). The 2016 Plan permits grants of options, SARs, restricted shares, restricted share units, unrestricted shares, deferred share units and performance awards. Under the terms of the 2016 Plan: (i) the exercise price of an option may not be less than the fair market value of an IHC share on the grant date and the terms of an option may not exceed 10 years from the grant date; and (ii) the exercise price of a SAR may not be less than the fair market value of an IHC share on the grant date and SAR terms may not exceed 10 years from the date of grant.   The fair value of an option award is estimated on the date of grant using the Black-Scholes option valuation model. In general, the vesting period for an option grant is 3 years. Restricted share units are valued at the quoted market price of the shares at the date of grant and generally vest over 3 years. Compensation costs for options and restricted share units are recognized over the stated vesting periods on a straight-line basis. The fair value of a SAR is calculated using the Black-Scholes valuation model at the grant date and each subsequent reporting period until settlement. Compensation cost is based on the proportionate amount of the requisite service that has been rendered to date. Once fully vested, changes in the fair value of a SAR continue to be recognized as compensation expense in the period of the change until settlement. The Company accounts for forfeitures of share-based compensation awards in the period that they occur.   At December 31, 2019, there were 391,120 shares available for future stock-based compensation grants under the 2016 Plan. The following table summarizes share-based compensation expense, which is included in selling, general and administrative expenses on the Consolidated Statements of Income, applicable to the IHC plans (by award type) for each of the years indicated (in thousands):

 

 

 

 

2019

 

2018

IHC’s Share-based Compensation Plan:

 

 

 

Stock options

 

$

1,940 

$

754 

Restricted stock units

 

 

292 

 

184 

SARs

 

 

442 

 

253 

 

 

 

 

 

 

Share-based compensation expense, pre-tax

 

 

2,674 

 

1,191 

Tax benefits

 

 

720 

 

358 

 

 

 

 

 

 

Share-based compensation expense, net

 

$

1,954 

$

833 

 

Stock Options

 

The Company’s stock option activity during 2019 was as follows:

 

 

Shares

 

Weighted- Average

 

 

Under Option

 

Exercise Price

 

 

 

 

 

 

December 31, 2018

 

567,384  

 

$

19.40 

Granted

 

424,380  

 

 

37.38 

Exercised

 

(202,717) 

 

 

9.96 

Forfeited

 

(4,000)

 

 

22.20

 

 

 

 

December 31, 2019

 

785,047  

 

$

31.54 

The weighted average grant-date fair-values of options granted during the years ended December 31, 2019 and 2018 were $8.31 and $9.05, respectively. The assumptions set forth in the table below were used to value the stock options granted during the periods indicated:

 

2019

 

2018

 

 

Weighted-average risk-free interest rate

2.32% 

 

2.86% 

Expected annual dividend rate per share

1.22% 

 

1.04% 

Expected volatility factor of the Company's common stock

28.97% 

 

32.42% 

Weighted-average expected term of options

3.5 years

 

4.0 years

In 2019, IHC received $269,000 in cash from the exercise of stock options with an aggregate intrinsic value of $5,207,000 and recognized $970,000 of tax benefits. Cash outflows in 2019 to satisfy employees’ income tax withholding obligations amounted to $2,397,000 for option exercises that were net settled in IHC shares. In 2018, IHC received $856,000 in cash from the exercise of stock options with an aggregate intrinsic value of $4,275,000 and recognized $810,000 of tax benefits. Cash outflows in 2018 to satisfy employees’ income tax withholding obligations amounted to $905,000 for option exercises that were net settled in IHC shares.

 

The following table summarizes information regarding options outstanding and exercisable:

 

 

December 31, 2019

 

 

Outstanding

 

Exercisable

 

 

 

 

 

Number of options

 

785,047

 

277,665

Weighted average exercise price per share

$

31.54

$

23.57

Aggregate intrinsic value for all options (in thousands)

$

8,272

$

5,140

Weighted average contractual term remaining

 

2.5 years

 

2.4 years

At December 31, 2019, the total unrecognized compensation cost related to IHC’s non-vested stock options was $2,962,000 and it is expected to be recognized as compensation expense over a weighted average period of 1.6 years.

 

 

Restricted Stock

 

The Company’s restricted stock activity during 2019 was as follows:

 

 

No. of

 

Weighted-Average

 

 

Non-vested

 

  Grant-Date

 

 

Shares

 

Fair Value

 

 

 

 

 

 

 

December 31, 2018

 

19,800  

 

$

31.84

 

Granted

 

9,900  

 

 

40.01

 

Vested

 

(9,900) 

 

 

28.61

 

 

 

 

 

 

 

 

December 31, 2019

 

19,800  

 

$

37.54

 

IHC granted 9,900 restricted stock units during each of the years ended December 31, 2019 and 2018 with weighted-average grant-date fair values of $40.01 and $38.49 per share, respectively. The total fair value of restricted stock units that vested in 2019 and 2018 was $389,000 and $350,000, respectively.

 

At December 31, 2019, the total unrecognized compensation cost related to non-vested restricted stock unit awards was $699,000 which is expected to be recognized as compensation expense over a weighted average period of 2.2 years.

 

SARs and Share-Based Performance Awards

 

IHC had 64,900 SAR awards outstanding at both December 31, 2019 and 2018. No SAR awards were granted or exercised in either 2019 or 2018. Included in Other Liabilities in the Company’s Consolidated Balance Sheets at December 31, 2019 and December 31, 2018 are liabilities of $717,000 and $275,000, respectively, pertaining to SARs.